DJ Hardman & Co Research: Tissue Regenix (TRX): Faster-than-anticipated recovery
Hardman & Co Research Hardman & Co Research: Tissue Regenix (TRX): Faster-than-anticipated recovery 19-Oct-2021 / 13:15 GMT/BST
-----------------------------------------------------------------------------------------------------------------------
Hardman & Co Research: Faster-than-anticipated recovery
Tissue Regenix (TRX) is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL) and bone (BioRinse). It has a broad portfolio of marketed regenerative medicine products for the biosurgery, orthopaedics and dental markets. Interim results showed early signs of the benefits of its strategic activities over the past two years - the focus on commercial relationships, capacity expansion, restructuring to service demand, and recovery in elective surgeries after the pandemic. If the demand and sales progress continues, TRX will become EBITDA- and EBIT-positive in fiscal 2022.
Please click on the link below for the full report:
https://www.hardmanandco.com/research/corporate-research/faster-than-anticipated-recovery/
If you are interested in meeting the company, you can register your interest by clicking on the above link
To contact us:
Hardman & Co Contact:
1 Frederick's Place
Martin Hall
London
mh@hardmanandco.com
EC2R 8AE
+44(0)20 3693 7075
www.hardmanandco.com
Follow us on Twitter @HardmanandCo
Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.
About Hardman & Co: For the past 25 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.
Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.
-----------------------------------------------------------------------------------------------------------------------
Dissemination of a CORPORATE NEWS, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.
-----------------------------------------------------------------------------------------------------------------------
End of Announcement - EQS News Service
1241808 19-Oct-2021
Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1241808&application_name=news
(END) Dow Jones Newswires
October 19, 2021 08:15 ET (12:15 GMT)
